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A 2016 Price Waterhouse Cooper Report, commissioned by the Australian Common-
wealth Government’s Organ and Tissue Authority, indicated that Australia had been
meeting its human ocular tissue for transplant needs. It further suggested that Australia
should consider exportation as a management strategy for excess tissue. Although we
do not seek to discuss how the Price Waterhouse Cooper Report determined that need
was being met, nor the potential value of exportation in this article, we propose that
Ocular Tissue for Research (OTR), and particularly identification of donors for research,
and timely access to freshdomestic tissue, be consideredas analternateor simultaneous
surplus management strategy. A robust OTR system could provide long-term domestic
support and investment into research and development of therapies in Australia. Such a
systemwould also provide ameaningful donation option for those otherwise unable to
donate for transplant. This article attempts to document, for the first time to our knowl-
edge, the current recovery and distribution processes of deceased OTR in Australia. It
maps the process steps, identifies the stakeholders and needs, discusses the limitations
and barriers, and proposes key policy and practice reform strategies that may assist in
improving access to OTR.
Translational Relevance: To improve and increase access to human ocular tissue for
research, and in turn, advance vision science and clinical application.
Introduction
The advancement of vision science and the develop-
ment of most new treatments, techniques, and diagnos-
tics is dependent on access to sufficient quantities of
well-characterized high-quality human ocular tissues.
Although the 2016 National Research Infrastructure
Roadmap1 includes calls for a national framework
regarding access to biological samples, to date, there
are no specific Ocular Tissue for Research (OTR)
national strategies in place to prepare Australia, as it
explores new technologies (e.g., tissue engineering and
stem cells), as well as provide ocular tissue for conven-
tional research needs (e.g., corneal diseases or retinal
material for diabetic eye disease, glaucoma, and age-
related macular degeneration).
Although some tissue samples can be obtained
from a living human, primarily identified andmanaged
by clinician-scientists and living donation programs,
the majority of vision science researchers are reliant
on deceased donation from consented voluntary and
altruistic donors. This, in turn, has made researchers
reliant on the deceased organ and tissue donation
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sector for donor identification, consent, recovery,
processing, and allocation.
As the Australian organ and tissue donation sector
has been historically focused, funded, and designed for
the purposes of transplant, OTR services were added
by way of an ad hoc by-product service, rather than as
a direct and unique area of planned service. However,
more recent developments through the emergence of
biobanks and the 2016 National Research Infrastruc-
ture Roadmap are changing this paradigm.
This article highlights the need for a coordinated
approach to deceased OTR and prompt collaborative
discussions with key stakeholders, to allow planning for
OTR use going forward.
The Current Process
The Researcher
In Australia, OTR is typically provided to
researchers by their closest Australian Eye Bank
(AUEB) (Adelaide, Brisbane, Melbourne, Perth, and
Sydney) or at times, the Biobank (The Australian
Ocular Biobank, Sydney). The researchers must
provide evidence of human research ethics approval
alongside information about their project, team
members, and the type of tissue they require. Depend-
ing on the research, theymay ask for a certain quantity,
tissue type (e.g., the retina or the cornea), and storage
preference (fresh or preserved or specific storage condi-
tion, for example, liquid nitrogen, –80°C, for nuclear
material or subsequent derivation of cell lines from
the tissue, and others). At times, they may also request
diseased or nondiseased (control) tissue, or tissue from
a donor with certain characteristics (age, smoking
status, and so on). The researcher is then notified by
the AUEB/Biobank if donated OTR matching their
request is available.
Due to uneven supply and demand, researchers may
go through periods without any OTR, and then be
provided with several in quick succession. Researchers
are required to plan their experiments around the avail-
ability accordingly, often having little time to collect
and utilize the tissue before it expires or before another
researcher lays claim to the tissue. Although a small
minority of researchers do budget for tissue service
costs, with preplanned recovery (removal) processes in
place with their local AUEB or Biobank, most do not,
and rely instead on tissue provided on a “no-cost”basis
by the AUEB. This may reflect the research process, for
example, additional experiments, changes in protocols,
or emergence of new techniques, meaning OTR needs
may change after the time of initial research grant
application or reflect emerging areas of new research.
The Organ and Tissue Sector
The process of determining deceased donors for
research varies among the Australian States and Terri-
tories, although it generally commences with the
donor coordinators located in the hospital setting.2
They ascertain willingness of an individual to donate
for transplant and/or research and training. Willing
donors (via their next-of-kin) indicate their donation
wish. The donor coordinators notify the AUEB when
potential donors are identified.
As the donation system in Australia is histori-
cally designed to support transplantation, only donors
who are potential eligible donors for transplantation
tend to progress in the system. The donors are then
triaged through a donor eligibility criteria pathway
before consent and recovery is performed. The eligi-
bility and donation pathway is outlined in Figure 1,
demonstrating the various steps necessary for triage
toward donation. Those eligible for transplantation are
consented (via their next-of-kin) prior to recovery of
their donation. This includes examination of medical,
surgical, and social donor history. Blood samples
analyzed and ocular tissue integrity and suitability are
examined closely. Ocular tissue that continues to meet
transplant eligibility criteria becomes transplant ocular
tissue. If the donor is eligible, and there are sched-
uled recipients awaiting a transplant, the AUEB recov-
ers the donation. They transfer the donation to the
AUEB for processing, and then allocate to a waiting
recipient.
Recovered ocular tissue that during the examination
process is deemed unsuitable for donation, does not
progress as transplant tissue. Instead, it becomes poten-
tial tissue for training and/or research, however, this
can only occur if the donor also consented for research
and/or training. Those not consented are discarded.
AUEB’s vary in terms of what they recover from
a donor, with some collecting just the corneoscle-
ral rim for corneal transplant, or occasionally the
whole globe for scleral need. Others routinely collect
the whole globe. Although the cornea and sclera are
needed for transplantation, the other parts of thewhole
globe are discarded, unless there are known researchers
with Human Research Ethics Committee approval
needing the donation and the donor has consented for
research use.
Alternatively, if the AUEB does not need tissue at
that time, or if the donor is ineligible for transplant,
the donor is not moved ahead in the pathway presented
in Figure 1. This means that potential OTR is not
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Figure 1. Current OTR pathway in Australia.
collected, even if the donor may have considered
donation for research only. Furthermore, this indicates
a potential pool of OTR donors who could otherwise
donate for research, if funding allowed for their recov-
ery by the AUEB.
Historically in Australia, ocular tissue was provided
to transplant recipients without charge, with cost
recovery services philanthropically supported.3
Although philanthropic and benevolent support (such
as Lions Clubs) remain, each AUEB is reimbursed for
the provision of a transplantable graft (e.g., cornea)
by Medicare in Australia or a recipient’s health insur-
ance company, with costs outlined on the Australian
Prosthesis List. In this model, tissue for transplan-
tation is funded, whereas nontransplant tissue (e.g.,
OTR) is not funded, resulting in an individual AUEB,
or rarely a researcher, incurring the cost.
Each AUEB has established cost recovery systems
independently. Some are able to provide the ocular
tissue to researchers without a fee, whereas others
require a cost recovery fee up to AU$500. Fee struc-
tures also take into consideration any preparation (e.g.,
dissection or provided whole) or preservation cost-
recovery needs, to meet the preservation requirements
of the researcher.
Research Needs
To date, there is no centralized registry in Australia
regarding OTR utility and need. Although individ-
ual AUEBs do record tissue recovered for transplant,
that later becomes OTR, their data do not merge
with other AUEBs/Biobanks, possible imports, and
other nonbank living procurement services, nor do
Australian authorities collect data on any human
material required or used for research. Therefore
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Figure 2. Proposed reform pathway to improve OTR access in Australia. Purple/filled boxes provide proposed strategy.
despite an Australian national research infrastructure
scoping review anticipated to commence in 20201 to
review and plan for access and allocation (e.g., via
Biobanks), today there is no clear picture of OTR
current or future need within Australia.
As an indicator of potential need, research
conducted by Stamer et al.,4 based in the United
States, identified in a voluntary survey of the Associ-
ation for Researchers in Vision and Ophthalmology’s
(ARVO) domestic and international members, that
vision science researchers had a strong interest in
using more tissue if it were easier to obtain. Although
no similar study has been performed in Australia,
we suspect the same may also be true of Australian
researchers, with research size and design adapted
(or reduced) to meet OTR availability. As a guide,
Stamer et al.4 also outlined that their respondents
required an estimated (mean) of 4 ± 11 human eyes
per month, and 31 ± 111 eyes per year, although this
may change if researchers had ready and routine access
to OTR.
Examining OTR Trends
Although OTR demand in Australia may not be
documented or tracked, there is an increasing volume
of medical research being conducted,5 and government
policy and research design is increasingly focused on
encouraging translational medicine, with concomitant
translation of basic science for human medical use.
Such translational work often requires greater quanti-
ties of human tissue.
For example, the emergence of increasingly sophis-
ticatedmolecular and cellular methods has created new
demands for OTR. These include multiple methods
in biological disciplines, including genomics, epigenet-
ics, and proteomics, as well as immunostaining, cell
culture, cell therapy, tissue engineering, and genetic
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engineering. Similarly, the development of new genetic
engineering approaches and single-cell RNA sequenc-
ing has created a greater requirement for access to
fresh tissue to assess expression profiles of individual
or cell-specific profiles.6 These innovations enable “big
data” approaches, with concomitant ability to under-
take analysis of very large datasets to discover statis-
tically significant associations through bioinformatic
approaches, for example, Kuiper et al.7 and Lin et al.8
To fully make use of these scenarios, researchers will be
reliant on having access to donor tissue from hundreds
or even thousands of individuals. Increased access to
OTR might prove a catalyst to such advancements in
the biomedical space.
In addition to investigations to further medical
knowledge, some of these techniques are being used
in clinical trials. The facilities, networks, and the
skills of AUEBs position them to not only provide
tissue for preclinical experiments and clinical trials
but to contribute through assessment of emerg-
ing genetic, cellular, and tissue engineered therapies,
and drug response changes in tissue or structural
changes (e.g. corneal cross-linking). Alongside deliver-
ing these therapies to clinicians, some of these thera-
pies will continue to require ocular tissue, provided by
AUEBs/Biobanks, for their process and preparation.9
Aside from the potential for new techniques and
big data, researchers may have specific requirements,
some of which will be different to the requirements
for donation or locally available OTR. Some experi-
mental techniques require fresh tissue to avoid artifacts
resulting from postmortem processes,6 for example
Lukowski et al.6 required retinas to be fewer than 15
hours postmortem. Other techniques require preserva-
tion methods not used within AUEB, such as cryop-
reservation for some immunofluorescence techniques.
Barriers to OTR
Numerous barriers prevent a steady and robust
supply of adequateOTR.We attempt to explore several
of these components in this section.
Diverting Transplant-Surplus to Research
The Price Waterhouse Cooper Report (PWCR)10
comments that Australia is meeting surgical ocular
tissue need and is in a surplus state. They suggested
that Australia should consider exporting surplus tissue
that is not required for transplant in Australia.
Although they do not explain how they define meeting
need, within such a scenario, we propose that a
“surplus status” occurs when donor coordinators
and/or AUEBs decline eligible donors because sched-
uled surgical transplant need has been met at that
time. As ocular tissue is time sensitive, the AUEBs may
not be able to transplant the tissue before it expires.
Currently, transplantation is the mainstream use of a
donation. Wherever possible, rather than recovering
excess tissue, wasting it, and incurring the associated
recovery costs (e.g., staffing), the AUEBs respectfully
declines the donation.
Although the PWCR intended to focus on
Australia’s transplant need and services, with their
export recommendation as a side emerging theme and
a logical first solution that would provide transplant
assistance to waiting recipients of another nation,
there remains no examination of domestic OTR use
as a surplus management strategy. As an alternative
or simultaneous proposal, surplus transplant eligible
(and ineligible) ocular tissue could still be utilized
in Australia, if cost-recovery mechanisms were there
to support research. Although not reviewed in the
PWCR, OTR need would meet other objectives of the
PWCR, such as investment into Australian Research
and Development (R&D) and preparing Australia,
and the donation sector, for the proposed transition
toward tissue engineering and cell therapy. Ironi-
cally, such future treatment options are impossible
without R&D conducted using human ocular tissue,
so retention of some fresh tissue, surplus-to-domestic-
transplant need (and recovery of nontransplant grade
tissue) could provide greater long-term potential for
Australia. Without adequate access to OTR, it is likely
that Australian researchers may either go without,
being unable to complete their research; modify their
experiments to meet access needs; or migrate their
work, and the development potential, outside of
Australia.
Domestic and International Obtainment of
OTR
Alternatively, researchers in Australia could import
OTR from other countries, such as the United States,
who do have surplus tissue, that is suitable and
consented for research needs.11 As the United States
also has a robust transplant-exportation system,12
such exportation for research may indeed be viable.
This would quickly increase access for laboratory-level
experimentation. There are no hard laws preventing
Australian researchers doing so, assuming adherence to
customs and import laws and ensuring that any human
trials using imported or research tissuemeet the criteria
of the Australian regulators.
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Although importation appears a viable option,
Australian vision science researchers do not appear
to import OTR. This may be because of logis-
tics, handling costs, and because the researcher may
need to navigate and then manage the relation-
ship with the importer or third-party distributor.
The practicalities of transporting tissues from distant
exporting nations in the northern hemisphere to
Australia is also a challenge, reducing access to the
much-needed fresh tissue, resulting in importation
of preserved (e.g., hypothermic stored) corneal tissue
only. Researchers who import would therefore be
restricted to research not requiring fresh tissue (though
remaining within an adequate death-to-preservation
period).13
Within Australia, access to fresh tissue for research
may be an issue because of the geographic size of the
country. However as most Australian eye researchers
are in east coast cities that house most of the
AUEBs/Biobanks and recovery allocation practices
are based on serving local first, then this access to
fresh tissue may not be an issue for most researchers.
Perth is the only exception, owing to its isolation
on the west coast, with flight times from east to
west taking 4.5 hours (on top of recovery, process-
ing, and land transport logistics). Therefore fresh OTR
needs, in Perth, are reliant on local self-sufficient
services from the Eye Bank of Western Australia.
For preserved tissue, Australia has similar death-to-
preservation time processes as other countries, and
shares similar recovery time, freight cost, and overland
transfer times as other larger geographic nations, such
as the United States, and as such, domestic preserva-
tion methods can be tailored to meet the researchers
needs.
Regardless of the nation or the donation recovery
systems in place, fresh tissue poses unique logistical and
practical challenges, particularly for research proto-
cols requiring fresh tissue within tight timeframes (e.g.,
within 2 hours of death). Such short time periods are
unpractical and unlikely to change, as donation services
must allow respectful grieving time to donor families,
complete all donation consent steps, and schedule in
the AUEB recovery team, prior to the recovery and
delivery to the researcher.
Proposing to import OTR from the northern
hemisphere, whereas the PWCR simultaneously
proposes to export surplus Australian transplant-
grade tissue to other countries for transplantation,
may sound absurd and inefficient but is not necessarily
so. This scenario draws on elements not discussed
in the PWCR, whereby the grade of the tissue may
predict its use and destination. This, however, raises
further questions, such as:
• What is research-grade and transplant-grade
tissue?
• Do researchers need access to transplant-grade
tissue, as well as nontransplant grade tissue, to
conduct comparative studies?
• Should transplant-grade tissue be allocated to
recipients today, or go toward research and future
therapies for future generations?
• Could donors, who are not triaged through the
eligibility process (as they do not meet transplant
criteria), also be recovered for research?
• Does death-to-preservation time influence use for
transplantation or research?
The current process implies that Australian
researchers typically receive nondiseased relatively
healthy tissue with some imperfection or donor
ineligibility that rendered the tissue not suitable for
donation.
Nontransplant Grade Tissue
As some researchers may specifically seek a diseased
eye or tissue from a donor of a specific charac-
teristic (e.g., keratoconus, that would not normally
progress to becoming a donor for transplant), the
recovery from nontransplant ineligible donors is essen-
tial. Access to such donors, with specific criteria, can
be problematic, especially in the instance of a rare
disease.14 The system is currently dependent on the
relationships between the AUEB and hospital donor
coordinators to liaise and identify possible consenting
donors who are ineligible for transplantation who may
wish to donate for research specific requests. Unfor-
tunately, identification and willingness to donate do
not automatically mean the donation is recovered.2
This will depend on funding to the AUEB, which
is restricted due to staffing constraints or processing
restrictions or space. Additionally, without funding
from the researcher or another avenue, the AUEB’s
willingness to recover tissue and prepare the tissue,
at no cost to the researcher, would become a limiting
factor for the recovery of OTR.
Development of systems to allow for ineligi-
ble transplant donors to donate is important for
research,14 and may be enhanced through the use
of consortia tissue management, assuming multi-
AUEB/Biobank-ethical conduct was established.
Consortia tissue management occurs when banks of
two different natures collaborate to share skills and
knowledge to recover from consenting donors of a
particular characteristic. For example, the AUEB
may be enlisted by the brain bank to recover ocular
tissue on behalf of the brain bank. This may occur if
Accessing OTR in Australia TVST | April 2020 | Vol. 9 | No. 5 | Article 4 | 7
researchers are examining the pathway or investigating
shared pathology between the brain and the eye, such
as in Alzheimer disease, or between the eye and other
tissue, such as ocular melanoma and melanoma of the
skin, or systematic disease within the same consented
donor.
In some instances, AUEBs are contacted by
researchers regarding known donors who premortem
arrange for their body to be donated to another
research bank (e.g., the brain bank), or to a specific
research project they participated in during their
lifetime. For example, someone who participated in
a research program examining macular degeneration
may consent for their eye to be examined by the
same vision science research team, postmortem, as
the final component of their participation in that
research project. In these instances, the AUEB staff
are contacted to perform the recovery and prepa-
ration because they have the appropriate recovery
skills. The recovered tissue is prepared and transferred
to the predetermined researcher/bank. Such cross-
bank consortia, although in occurrence in Australia,
are not commonplace within the vision science
sector.
Access to OTR Type
Without a national registry for OTR need and
utility, we cannot determine the types of OTR that
are routinely required by researchers, for example,
the cornea, lens, retina, and so on. Although the
Stamer et al.4 survey did not ask respondents to
clarify the type of tissue they required, they did
collect information on the characteristics and section
affiliations of their respondents. This may assist in
indicating OTR type need of the participating ARVO
Members, with their main respondents being cornea
(21%), glaucoma (17%), retina cell biology (16%), and
retina (10%).
Although Stamer et al.4 did not delve further into
why the main respondents were from the cornea and
glaucoma sectors, we propose that this may be based
on their existing relationship with their local eye
bank, whose transplant services provide for cornea and
glaucoma surgical management. This means that there
is a greater likelihood that tissue recovered for those
transplants may become OTR if found ineligible for
transplant. This is predominantly so if theAUEB tends
to recover the corneoscleral rim as routine, as opposed
to the whole globe. Although this recovery process
works for the transplant sector and prevents additional
processing time, cost, and discard of other ocular
parts, it does not necessarily work for noncorneal or
glaucoma OTR needs. Although we were unable to
find evidence, we propose that this may lead to faster
and greater R&D success in the cornea and glaucoma
sectors, as opposed to other areas of ocular enquiry in
years to come.
Other Access Avenues
Occasionally, consenting nondeceased OTR is
recovered from the operating theatre (e.g., the
nontransplanted corneoscleral rim). Although the
researcher may be known to the AUEB and ethics
approved, the recovery is often arranged between the
researcher and surgeon for a specific project. Collec-
tion practices are outside of the management of the
AUEB, with responsibility placed on the transplant
facility (hospital, day surgery) and ethics-approved
researcher, to ensure donor consent is in place, and
safe handling practices are followed prior to handing
the OTR to the researcher.15 Of note, consenting
living recipient/patients may also donate excised
OTR (e.g., specimens, tissue of unknown etiology,
or corneal buttons). Although such living donation
programs and specimen collections are beyond the
scope of this article, they indicate another source of
OTR.
Competing Demands for Nontransplant
Tissue
The increased interest in lamella surgical techniques
in recent decades has also impacted OTR access, with
excess recovered corneal tissue being fully utilized
by physicians as they perfect these new techniques.
Although we were unable to find any published data
pertaining to tissue allocation for training use in
Australia,16 the Eye Bank Association of America
(EBAA) states that the United States, “experience[d]
a slight decline in the number of corneas provided for
research from the highs of 2011 and 2012, [and can be]
explained by the concurrent increase in tissue allocated
to education and training purposes.”Corcoran16 recalls
“that this period coincides with the development of
more technically challenging endothelial keratoplasty
procedures.’’
As new surgical techniques continue to be explored,
with subsequent surgeon training essential, and animal
tissue remaining the only simulated precut training
option, then we consider the competing demands with
tissue-for-training as a permanent tissue utility require-
ment in Australia (unless virtual reality simulation
systems are developed). Therefore other avenues for
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OTR access are required to ensure tissue-for-training
is simultaneously maintained.
Unlocking the Barriers to Access
Although there may be a desire to support greater
access to OTR, there are several aspects of current
practice in Australia that require address:
1. There is a lack of information available to prospec-
tive donors and the next-of-kin regarding their
option to donate to research.3
2. There is no central shared record/registry for OTR
other than via the local AUEB/Biobank. This
means that researchers may not be aware of tissue
available elsewhere, and vice versa.
◦ Without a shared record/registry, the national
OTR need, utility, or importation numbers
remains unclear.
◦ As OTR falls outside of the transplant sector’s
focal area, there appears to be no central body who
would be responsible for the collection of the data
or management of a researcher registry.
3. Tissue-for-training remains a competing need.
Mechanisms to simultaneously support training
and OTR are required, although development of
virtual reality simulations could be a useful alterna-
tive.
4. Researchers themselves do not routinely factor in
OTR cost recovery into grant proposals and project
budgets. Therefore they are reliant on sporadic
access to no or low-cost domestic tissue, and are
unable to afford imports or to pay cost recovery to
the AUEB.
5. Researchers with specific donor criteria (e.g., short
postmortem times or specific characteristics, such as
a female smoker over the age of 50, or a male Pacific
Islander with keratoconus) restrict their access to
OTR. This is because OTR is not made-to-order
and cannot be promised.
6. The conversation regarding demand in Australia
needs to be expanded to include examination of
OTR need. Its absence to date has resulted in expor-
tation as the only surplus management strategy
proposed to the Organ and Tissue Authority in the
PWCR.
7. Access to fresh tissue remains reliant on proximity
to local AUEBs and their collection methods.
8. The role and perception of the AUEB custodian
needs to transition beyond that of a transplant
tissue provider to one in which they are the custo-
dian of the donation,17 servicing a wide range of
donor and public and sector needs, be that trans-
plant, research, and/or training (with the poten-
Table. The Barcelona Principles 201819
PRINCIPLE 9: Ensure Ethical Practice and Governance
of Research (Nontherapeutic) Requiring Cells Tissue
and Organs (CTO). Strategy:
I. Ensure consent for research.
II. Provide tissue to research and technical
development projects where all parties
demonstrate ethically sound practices and
processes.
III. Ensure any intended research for which CTO is
requested has been designed, and will be
conducted, in accordance with jurisdictional law,
and regulations that govern the ethical use of
human tissue (inclusive of the Declaration of
Helsinki/International Ethical Guidelines for
Health-related Research Involving Humans), and:
a. obtain approval from a qualified human
research ethics committee.
b. work with scientific journals and peer
associations/societies to promulgate scientific
standards that honor the ethical consent of CTO
for research.
IV. Researchers should verify that the eye bank
providing the tissue has appropriate credentials,
policies, and practices, and is transparent and
open to scrutiny (e.g., demonstrating their ethical
consent process for obtaining and allocating CTO
for research or further attenuation/
commercialization).
V. Scientific journals should establish a mechanism
to confirm research is conducted on ethically
obtained CTO.
tial to lead the development of simulated training
options).
The described barriers are not unique to Australia.
The United States is the only known nation to address
such barriers through a collaborative EBAA and
ARVO initiative. Collectively, they have developed
a webportal, EyeFind, designed to connect US eye
bankers with researchers.4,11,16,18
Curcio18 suggested that those involved in research
must also make changes. She highlighted similar strate-
gies outlined in Principle 9 of The Barcelona Princi-
ples (Table),19 which are a bioethical framework devel-
oped by the Global Alliance of Eye Bank Associations
in conjunction with the global eye care and corneal
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communities. Curcio18 proposed that researchers must
describe their human tissue selection methods in their
manuscripts, and that organizations providing the
tissue must be named as authors or acknowledged
partners. This highlights the collaborative partnership
and ensures that there is significant demonstration of
criteria for ethical and appropriate recovery and alloca-
tion.
Reform Strategies
The research, transplant, and donation sectors are
interconnected, unable to improve, progress, or resolve
issues without co-operation. Researchers are reliant on
OTR to develop new treatment options. The transplant
sector is simultaneously reliant onR&D to provide new
treatment options. Finally, the donation sector is also
reliant on the discovery of new technologies to reduce
the long-term burden and strain on donation services.
This will ultimately lead to a point in which there is a
reduced need for donations, as other approaches can be
used.
Regulation has not kept pace in the ever-changing
research and deceased donation sectors,17 and is
unlikely to do so for some time. Therefore we propose
the sector itself take a leadership role and promote
change by engagement of researchers, organ and tissue
professionals, and transplant professionals to develop
a policy and practice reform strategy that improves
access to OTR for Australian researchers, while simul-
taneously ensuring such access does not compromise
donor wishes, hinder transplant needs, or undermine
tissue for training needs or potential exportation. We
believe, if done in a systematic manner, Australia could
become a leader in OTR practice and retain a viable
vision science research sector.
We propose a series of policy and practice strate-
gies are developed to unblock the barriers we described
earlier via stakeholders, including the Organ and
Tissue Authority, AUEBs/Biobanks, vision science
researchers, bioethicists and biological health lawyers,
and the professional peer associations of these groups.
These strategies could include:
1. A recommendation that all researchers automati-
cally factor in average OTR costs into their grants
and budgets or researchers work with their funding
bodies to develop new OTR funding avenues.
2. Adherence to The Barcelona Principles: Principle 9
(Table)19; all published research to include informa-
tion regarding where and how they obtained OTR
and its ethical origin.
3. Placement of an additional “Register for Research”
box on the national Medicare donor register page.
This will assist in identifying OTR donors and
could assist in identifying donors with specific
disease characteristics.14
4. Development of a public information campaign,
reemphasizing consent for research options to
donate nontransplant grade tissue to research,
and/or research-only donations. Information
could be made available alongside information
on donation for transplantation.
5. Provision of information via a health provider
(e.g., a general practitioner, ophthalmologist,
optometrist, nurse) directly to patients, outlining
their option to donate for research. This could
also assist in increasing rare, diseased, or specific
demographic donation requests,20,21 as otherwise
such donors may not consider donation on their
death.
6. Allowance of those ineligible for transplantation,
who would otherwise exit the donation pathway
preconsent, to be consented and recovered as OTR
donation only.
a. Funding options will need to be addressed regard-
ing provision of OTR at either a no cost and/or
at a fee subsidized by the Australian Govern-
ment or another avenue, as such methods may
risk the sustainability of the AUEB/Biobank. Our
proposal is outlined in Figure 2.
7. Development of a national co-operatively managed
register to allow ethics-approved researchers to
connect directly with their AUEB/Biobank to
match their OTR need with available donations.
This system could allow:
a. The AUEB/Biobank to arrange for ethics-
approved imports or cross-state/territory OTR,
as required by researchers. This would allevi-
ate navigation issues for the researcher, who
would otherwise have to register with multiple
providers, work with distributors, manage the
logistics and confirmation of the ethical validity
of the donation and involved parties. This ensures
Australian research, involving domestic or foreign
donors, meet the ethical norms and legal principles
that govern Australia, and those outlined within
The Barcelona Principles, without limiting the
potential of Australian R&D.
b. Ensure Australia has an OTR tracking and data
monitoring system in place.
c. Improve relations between AUEB/Biobank and
researchers.
d. Open up opportunities for collaboration with
other national and international eye banks,
researchers, consortia, and donation agencies.
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e. Ensuing cross-sector transparency to the
Australian public and government.
Conclusions
Although access to human tissue of any quantity
and size is an end-of-life donation, rather than a
consumable that can be demanded, if there is an unmet
need for OTR, and there are donors whose donation
wishes have not been met, then steps could be taken to
ethically and practically meet the wishes and needs of
all parties.
Barriers to OTR include research budgeting and
other cost avenues, limited access to the tissue—and
in particular fresh tissue—lack of donor information,3
and a system that has historically focused on trans-
plantation. Although regulatory change is a primary
requirement, it is unlikely to occur in the short-term.
As such, we call on sector stakeholders to strengthen
their relations as leaders of this field and work collab-
oratively to resolve and remove nonregulatory barri-
ers to OTR. In doing so, Australia will retain and
build its position as a prominent leader in the vision
sciences.
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